<DOC>
	<DOCNO>NCT00103935</DOCNO>
	<brief_summary>Exenatide LAR long-acting release formulation exenatide , twice-daily dosage form currently investigation potential treatment people type 2 diabetes mellitus . This study ass safety , tolerability , pharmacokinetics Exenatide LAR administer weekly subcutaneous injection people type 2 diabetes mellitus .</brief_summary>
	<brief_title>Study Examining Exenatide Long-Acting Release Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Has type 2 diabetes treat either : *A stable regimen metformin minimum 3 month , and/or *Diet modification exercise minimum 3 month . Has HbA1c 7.1 % 11.0 % , inclusive . Has body mass index ( BMI ) 25 kg/m2 45 kg/m2 , inclusive . Received investigational drug within 3 month prior screen . Is currently treat follow excluded medication : *Thiazolidinediones within 3 month screen ; * Sulfonylureas within 3 month screen ; * Insulin within 1 year screening . Participated previously exenatide clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>long act release</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>